Bausch + Lomb (NYSE:BLCO) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Bausch + Lomb (NYSE:BLCO) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $23.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Royal Bank of Canada dropped their price objective on shares of Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 29th. Morgan Stanley lowered shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a research note on Monday, December 2nd. Wells Fargo & Company dropped their price objective on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, January 16th. Citigroup lowered shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $24.00 to $22.00 in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Bausch + Lomb has a consensus rating of “Hold” and an average target price of $20.25.

Bausch + Lomb Stock Down 0.1 %

Bausch + Lomb stock opened at $16.40 on Tuesday. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The firm has a market capitalization of $5.78 billion, a price-to-earnings ratio of -15.61, a price-to-earnings-growth ratio of 2.13 and a beta of 0.46. The firm’s fifty day moving average price is $17.51 and its two-hundred day moving average price is $18.16. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.

Institutional Trading of Bausch + Lomb

A number of large investors have recently added to or reduced their stakes in BLCO. Alberta Investment Management Corp boosted its position in Bausch + Lomb by 36.0% during the fourth quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock worth $54,328,000 after purchasing an additional 796,400 shares during the period. River Road Asset Management LLC boosted its position in Bausch + Lomb by 4.4% during the third quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock worth $38,974,000 after purchasing an additional 85,987 shares during the period. Whitebox Advisors LLC boosted its position in Bausch + Lomb by 16.1% during the fourth quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company’s stock worth $26,062,000 after purchasing an additional 199,856 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock worth $21,996,000 after purchasing an additional 414,138 shares during the period. Finally, King Street Capital Management L.P. boosted its position in Bausch + Lomb by 55.2% during the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company’s stock worth $20,522,000 after purchasing an additional 404,256 shares during the period. Hedge funds and other institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.